PSMD8 Activators

PSMD8 come from a class of compounds known as proteasome inhibitors, which share a common function of impeding the proteasome's ability to degrade proteins. The proteasome is a complex cellular machine responsible for breaking down and recycling proteins that have been tagged for destruction. When proteasome inhibitors such as MG-132, Bortezomib, Carfilzomib, MLN2238, Oprozomib, Marizomib, Lactacystin, Epoxomicin, Delanzomib, Ixazomib, and Salinosporamide A interfere with this process, it leads to an accumulation of polyubiquitinated proteins within the cell. This accumulation signals the cell to adapt by attempting to restore the balance of protein degradation and synthesis.

Cells may increase the production of proteasome subunits as a compensatory mechanism. PSMD8, being a regulatory subunit of the proteasome, is one of the components whose activation is upregulated in this context. The inhibition of the proteasome's function by compounds such as Bortezomib, which is also known by the brand name Velcade, prompts the cell to enhance the expression of proteasome subunits including PSMD8. This is a direct cellular response to the blocked degradation pathway, aiming to maintain protein homeostasis. Similarly, irreversible proteasome inhibitors like Carfilzomib and Lactacystin bind to the proteasome and disrupt its activity, thereby triggering an increase in PSMD8 to counteract the impaired protein clearance. The consistent theme across the action of these chemical activators is the cellular drive to maintain proteostasis through the upregulation of proteasome subunits, including PSMD8, to compensate for the compromised proteolytic function.